Bacterial translocation. Can sucralfate have a role in prevention?

Abstract

Bacterial translocation (BT) is still being believed to be a major problem in patients with several different serious illnesses including obstructive icter. A series of preventive procedures has been tried. (-ie. gout decontamination enteral nutrition, different medications... etc). For this purpose only one study with sucralphate (low dose) + fibroblast growth factor has been found in the literature. In our study we tried sucralphat with routine mucosal protective dose orally to prevent BT in rats. Fifty male Sparague. Dawley rats wheighing 455-490g were divided to five equal number groups. After routine laboratory living conditions and standard feeding, the following procedures were applied to each group: GroupI (Controle grup): Top water, standard food, and 2 ml/day saline gavage for 5 days. GroupII (Ligation group): Top water, standard food, 2 ml/day saline gavage for five days. GroupIII (Sucralphate group): 60mg/kg/day sucralphate p.o instead of saline. GroupIV (Neomycine group): 20mg/kg/day neomycine p.o instead of saline and sucralphate. GroupV (Sucralphate+Neomycine group): 60mg/kg/day sucralphate+20mg/kg/day neomycine p.o Common bile duct ligation(CBDL) applied in groups II-V under pentothal anesthesia on 3rd days of the procedures above to cause BT. BT was investigated four days after CBDL procedures. BT rates found were 20%, 90%, 30%, 20%, and 30% in Group I, II, III, IV and V respectively. Our findings suggest that, enteral sucralphate seems to be a protective agent in BT with the advantages of safety and cost effectiveness.